A detailed history of Versant Capital Management, Inc transactions in Genmab A/S stock. As of the latest transaction made, Versant Capital Management, Inc holds 722 shares of GMAB stock, worth $15,501. This represents 0.0% of its overall portfolio holdings.

Number of Shares
722
Holding current value
$15,501
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 02, 2025

BUY
$20.02 - $24.15 $14,454 - $17,436
722 New
722 $15,000
Q1 2023

Apr 10, 2023

BUY
$34.88 - $43.22 $3,069 - $3,803
88 New
88 $3,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.1B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.